Fifth edition of the initiative, in collaboration with the Indian Cancer Society (ICS), aims to support underprivileged cancer patients

FinTech BizNews Service
Mumbai, 16 November, 2026: HDFC Asset Management Company Limited (HDFC AMC), investment manager to HDFC Mutual Fund, announces the fifth edition of its Cancer Cure series with the launch of the HDFC Charity Fund for Cancer Cure (Feb 2030), in collaboration with the ICS. The Scheme allows investors to contribute towards the treatment of underprivileged cancer patients by donating a portion of the distribution income earned through the IDCW option. The NFO opens on November 16, 2026, and closes on November 30, 2026.
According to ICMR-NCDIR, India witnessed an estimated 14,61,427 new cancer cases in 2022, with a new diagnosis occurring approximately every 22 seconds. For many families, the financial burden of treatment remains a significant barrier to accessing timely care.
Launched in 2011 as India’s first cancer fund, the Cancer Cure series has raised Rs292.41 crore for ICS, including HDFC AMC’s direct contributions (as of September 2026), with Rs273.28 crore disbursed towards the treatment of 17,435 patients across 22 hospitals (as of August 31, 2026). Notably, nearly one in four patients supported through the initiative was a child aged 15 or below.
Through this Scheme, investors can choose to donate 50% or 75% of their IDCW to ICS, with HDFC AMC matching the contribution, subject to a limit of ₹16 crore per financial year. The investment amount will return to investors upon maturity. HDFC AMC has also waived the investment management and advisory fee to ensure that a greater share of the proceeds can support the cause.
Commenting on the announcement, Mr. Navneet Munot, Managing Director and Chief Executive Officer, HDFC Asset Management Company Limited, said, “At HDFC AMC, we believe that the true measure of an institution's success lies not just in the value it creates, but also in the difference it makes to people's lives. Over the years, the Cancer Cure initiative has brought together investors, the industry and a committed partner like the Indian Cancer Society to address a cause that affects countless families. The Rs292 crore contribution and the thousands of patients who have received support are a testament to what sustained collective effort can achieve. We hope this fifth edition will build on that legacy and inspire more people to become part of a cause where every contribution can make a meaningful difference.”
Ms. Usha Thorat, Indian Cancer Society, added, “For a family facing cancer, access to timely treatment can make all the difference. However, the cost of care often puts treatment beyond the reach of those who need it most. The support received through HDFC Mutual Fund's Cancer Cure series has enabled us to extend financial assistance to over 17,000 patients across 22 hospitals. Beyond the financial support, this initiative has helped bring hope to families at an extremely difficult time. We are grateful for this continued partnership and look forward to reaching many more patients through its fifth edition.”